Attana at Antibody Engineering & Design

Name: Attana at Antibody Engineering & Design
Start: 2011-02-22T00:00:00.000+01:00
End: 2011-02-24T23:59:59.000+01:00
Location: InterCity Hotel, Frankfurt

Tid 22 Februari 2011 – 24 Februari 2011

Plats InterCity Hotel, Frankfurt

Join our panel discussion- Wed 23rd @ 16.40 Biologically relevant information- improving success of clinical trials! Panelists: Dr Teodor Aastrup, CEO, Attana Dr Juan Carlos Almagro, Research Fellow, Head, Antibody Design Unit, Centocor Dr Jesus Zurdo, Head of Innovation LCM Development Services, Lonza Dr Alain Beck, Head of Physico Chemistry, Centre d'Immunologie Pierre Fabre The panel discussion will be introduced with a presentation by Dr Jesus Zurdo, Head of Innovation LCM Development Services with Lonza on Managing development risks in biopharmaceuticals through lead optimisation and early analytical tools at 16.20. The AED Conference is dedicated to accelerating the development of therapeutic antibodies through engineering approaches.

Kategorier

biotech
attana 200
biologically relevant information
antibody engineering and design
attana
teodor aastrup

Relaterat innehåll

1 Februari 2010 14:36

Biosensor- Attana Cell 200, label free, real time kinetics on cells

Revolutionary Swedish invention can potentially improve drug development! Attana AB introduces the Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body.

18 Oktober 2009 16:24

Attana's core business!

View article in Innovations in Pharmaceutical Technology (IPT), a brief overview of Attana's core business. http://www.iptonline.com/viewinn.asp?cat=2&article=285

14 September 2010 15:30

Fight against cancer - Attana's collaborator interviewed

Attana's collaborator at Gothenburg University, Dr. Sture Lindegren, is interviewed about a possible new cure for ovarian cancers. Using the Attana Cell 200 instrument, Dr. Lindegren and his team are testing antibodies as carriers of radionuclide that target cancer cells directly instead of affecting the whole body as current cancer therapies do.